Loading...
Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $1.5M Total Trade · DGFT Verified
Protech BIO Systems Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.5M across 2 products in 2 therapeutic categories. Based on 92 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Imipenem ($950.0K), Ketorolac ($598.5K), .
Protech Bio Systems Private Limited, established on November 6, 1998, is a privately held pharmaceutical company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24239DL1998PTC096960. As of January 1, 2026, Protech Bio Systems has an authorized capital of ₹6.50 crore and a paid-up capital of ₹2.62 crore. The company operates in the manufacturing sector, focusing on the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Protech Bio Systems is unlisted and has a workforce of approximately 60 employees.
Protech BIO Systems Private Limited operates across 2 therapeutic categories, with Advanced Antibiotics (61.3%), Analgesics & Antipyretics (38.7%), representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Advanced Antibiotics
1 products · 61.3% · $950.0K
Analgesics & Antipyretics
1 products · 38.7% · $598.5K
Protech BIO Systems Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Imipenem | Advanced Antibiotics | $950.0K | 19 | 2.8% |
Headquarters, ownership, manufacturing facilities, and key leadership
Protech Bio Systems Private Limited, established on November 6, 1998, is a privately held pharmaceutical company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24239DL1998PTC096960. As of January 1, 2026, Protech Bio Systems has an authorized capital of ₹6.50 crore and a paid-up capital of ₹2.62 crore. The company operates in the manufacturing sector, focusing on the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Protech Bio Systems is unlisted and has a workforce of approximately 60 employees.
Protech Bio Systems Private Limited operates manufacturing facilities in New Delhi, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the capacities and certifications of these facilities are not publicly disclosed.
| 5 |
| 2 | Ketorolac | Analgesics & Antipyretics | $598.5K | 73 | 0.5% | 12 |
Protech BIO Systems Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $1.5M. The top category is Advanced Antibiotics (61.3% of portfolio), followed by Analgesics & Antipyretics (38.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.
Shipment-level records, pricing & buyer contacts for Protech BIO Systems Private Limited.
Request DemoThe leadership team at Protech Bio Systems Private Limited comprises:
These individuals are responsible for the strategic direction and operational management of the company.
Regulated market presence, emerging market penetration, and geographic strategy
Protech Bio Systems Private Limited's export activities, as per TransData Nexus proprietary trade data from 2022 to 2026, include:
Specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available.
Protech Bio Systems Private Limited's export data indicates a focus on Advanced Antibiotics and Analgesics & Antipyretics, which are critical in emerging markets. However, specific information regarding the company's penetration in Africa, Latin America, and Southeast Asia, as well as WHO prequalification status, is not publicly disclosed.
Protech Bio Systems Private Limited's export portfolio is concentrated in two products across two therapeutic categories, with a 100% concentration in the top five products. This indicates a focused approach, potentially reducing diversification and increasing concentration risk. The strategic direction appears to be centered on these specific products, though further details on geographic diversification are not publicly available.
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
Specific information regarding Protech Bio Systems Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available.
Details regarding Protech Bio Systems Private Limited's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly disclosed.
Specific information regarding Protech Bio Systems Private Limited's Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) is not publicly available.
There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Protech Bio Systems Private Limited.
Market share comparison, key differentiators, and strategic analysis
Protech Bio Systems Private Limited operates in the pharmaceutical sector, focusing on finished pharmaceutical formulations. While specific competitors in overlapping categories are not identified, the company's export data indicates a focus on Advanced Antibiotics and Analgesics & Antipyretics. The market share for its top products, such as Imipenem (2.8%) and Ketorolac (0.5%), suggests a presence in these therapeutic areas, though detailed market share comparisons and head-to-head analyses are not publicly available.
Protech Bio Systems Private Limited's key differentiators include its focus on specific therapeutic categories—Advanced Antibiotics and Analgesics & Antipyretics—and a concentrated product portfolio. However, the lack of diversification in its product range may limit its ability to mitigate risks associated with market fluctuations in these specific areas.
Protech Bio Systems Private Limited's current strategic direction appears to be centered on the production and export of specific pharmaceutical formulations. The company's future outlook would benefit from diversification in its product portfolio and expansion into additional therapeutic areas to enhance resilience and growth potential.
Track record assessment, certifications to verify, and pre-order checks
Protech Bio Systems Private Limited's export data indicates a focused approach with a total export value of $1.5 million USD across 92 shipments. The company's portfolio concentration, with top products accounting for 100% of exports, suggests a reliance on a limited product range. While the company has a consistent export track record, the lack of diversification may impact its ability to adapt to changing market demands.
Importers should verify the following certifications when considering Protech Bio Systems Private Limited as a supplier:
To verify these certifications, importers should contact the respective regulatory bodies or request copies of the certificates directly from Protech Bio Systems Private Limited.
When conducting due diligence on Protech Bio Systems Private Limited, consider the following steps:
Red flags to watch for include a lack of diversification in the product portfolio, limited regulatory approvals, and any history of regulatory non-compliance. Recommended pre-order checks involve obtaining copies of certifications, reviewing recent inspection reports, and assessing the company's reputation in the industry.
Protech BIO Systems Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Imipenem ($950.0K), Ketorolac ($598.5K). Total export value is $1.5M.
Protech BIO Systems Private Limited's total pharmaceutical export value is $1.5M, based on 92 verified shipments recorded in Indian Customs (DGFT) data.
Protech BIO Systems Private Limited exports across 2 therapeutic categories. The largest are Advanced Antibiotics (61.3%, 1 products), Analgesics & Antipyretics (38.7%, 1 products).
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Products Tracked
2 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.